240 related articles for article (PubMed ID: 36745965)
1. Spatiotemporal perspectives on tuberculosis chemotherapy.
Zhu J; Liu YJ; Fortune SM
Curr Opin Microbiol; 2023 Apr; 72():102266. PubMed ID: 36745965
[TBL] [Abstract][Full Text] [Related]
2. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
3. Mycobacterium tuberculosis infection of host cells in space and time.
Bussi C; Gutierrez MG
FEMS Microbiol Rev; 2019 Jul; 43(4):341-361. PubMed ID: 30916769
[TBL] [Abstract][Full Text] [Related]
4. Host-directed therapy targeting the Mycobacterium tuberculosis granuloma: a review.
Kiran D; Podell BK; Chambers M; Basaraba RJ
Semin Immunopathol; 2016 Mar; 38(2):167-83. PubMed ID: 26510950
[TBL] [Abstract][Full Text] [Related]
5. Dissecting Host-Pathogen Interactions in TB Using Systems-Based Omic Approaches.
Borah K; Xu Y; McFadden J
Front Immunol; 2021; 12():762315. PubMed ID: 34795672
[TBL] [Abstract][Full Text] [Related]
6. Innate Immune Defenses in Human Tuberculosis: An Overview of the Interactions between Mycobacterium tuberculosis and Innate Immune Cells.
Sia JK; Georgieva M; Rengarajan J
J Immunol Res; 2015; 2015():747543. PubMed ID: 26258152
[TBL] [Abstract][Full Text] [Related]
7. Understanding the Reciprocal Interplay Between Antibiotics and Host Immune System: How Can We Improve the Anti-Mycobacterial Activity of Current Drugs to Better Control Tuberculosis?
Park HE; Lee W; Shin MK; Shin SJ
Front Immunol; 2021; 12():703060. PubMed ID: 34262571
[TBL] [Abstract][Full Text] [Related]
8. Heterogeneous Host-Pathogen Encounters Coordinate Antibiotic Resilience in Mycobacterium tuberculosis.
Mishra R; Yadav V; Guha M; Singh A
Trends Microbiol; 2021 Jul; 29(7):606-620. PubMed ID: 33309526
[TBL] [Abstract][Full Text] [Related]
9.
Shim D; Kim H; Shin SJ
Front Immunol; 2020; 11():910. PubMed ID: 32477367
[TBL] [Abstract][Full Text] [Related]
10. Genome wide approaches discover novel Mycobacterium tuberculosis antigens as correlates of infection, disease, immunity and targets for vaccination.
Coppola M; Ottenhoff TH
Semin Immunol; 2018 Oct; 39():88-101. PubMed ID: 30327124
[TBL] [Abstract][Full Text] [Related]
11. Transcriptomic Signatures Predict Regulators of Drug Synergy and Clinical Regimen Efficacy against Tuberculosis.
Ma S; Jaipalli S; Larkins-Ford J; Lohmiller J; Aldridge BB; Sherman DR; Chandrasekaran S
mBio; 2019 Nov; 10(6):. PubMed ID: 31719182
[TBL] [Abstract][Full Text] [Related]
12. Of tuberculosis and non-tuberculous mycobacterial infections - a comparative analysis of epidemiology, diagnosis and treatment.
Gopalaswamy R; Shanmugam S; Mondal R; Subbian S
J Biomed Sci; 2020 Jun; 27(1):74. PubMed ID: 32552732
[TBL] [Abstract][Full Text] [Related]
13. Harnessing Biological Insight to Accelerate Tuberculosis Drug Discovery.
de Wet TJ; Warner DF; Mizrahi V
Acc Chem Res; 2019 Aug; 52(8):2340-2348. PubMed ID: 31361123
[TBL] [Abstract][Full Text] [Related]
14. The role of epigenetics, bacterial and host factors in progression of Mycobacterium tuberculosis infection.
Marimani M; Ahmad A; Duse A
Tuberculosis (Edinb); 2018 Dec; 113():200-214. PubMed ID: 30514504
[TBL] [Abstract][Full Text] [Related]
15. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
Tomioka H
Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
[TBL] [Abstract][Full Text] [Related]
16.
Bo H; Moure UAE; Yang Y; Pan J; Li L; Wang M; Ke X; Cui H
Front Cell Infect Microbiol; 2023; 13():1062963. PubMed ID: 36936766
[No Abstract] [Full Text] [Related]
17. Natural and trained innate immunity against Mycobacterium tuberculosis.
Ferluga J; Yasmin H; Al-Ahdal MN; Bhakta S; Kishore U
Immunobiology; 2020 May; 225(3):151951. PubMed ID: 32423788
[TBL] [Abstract][Full Text] [Related]
18. Rifampicin exposure reveals within-host Mycobacterium tuberculosis diversity in patients with delayed culture conversion.
Genestet C; Hodille E; Barbry A; Berland JL; Hoffmann J; Westeel E; Bastian F; Guichardant M; Venner S; Lina G; Ginevra C; Ader F; Goutelle S; Dumitrescu O
PLoS Pathog; 2021 Jun; 17(6):e1009643. PubMed ID: 34166469
[TBL] [Abstract][Full Text] [Related]
19. Differences in IgG responses against infection phase related Mycobacterium tuberculosis (Mtb) specific antigens in individuals exposed or not to Mtb correlate with control of TB infection and progression.
Coppola M; Arroyo L; van Meijgaarden KE; Franken KL; Geluk A; Barrera LF; Ottenhoff THM
Tuberculosis (Edinb); 2017 Sep; 106():25-32. PubMed ID: 28802401
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
